New findings could help improve development of drugs for addiction

Scientists from the Florida campus of The Scripps Research Institute have described findings that could enable the development of more effective drugs for addiction with fewer side effects.

The study, published in the August 2, 2013 issue of the Journal of Biological Chemistry, showed in a combination of cell and animal studies that one active compound maintains a strong bias towards a single , providing insight into what future drugs could look like.

The compound examined in the study, known as 6'- guanidinonaltrindole (6'-GNTI), targets the kappa (KOR). Located on , KOR plays a role in the release of dopamine, a neurotransmitter that plays a key role in . Drugs of abuse often cause the brain to release large amounts of dopamine, flooding the brain's reward system and reinforcing the addictive cycle.

"There are a number of drug discovery efforts ongoing for KOR," said Laura Bohn, a TSRI associate professor, who led the study. "The ultimate question is how this receptor should be acted upon to achieve the best therapeutic effects. Our study identifies a marker that shows how things normally happen in live neurons—a critically important secondary test to evaluate potential compounds."

While KOR has become the focus for drug discovery efforts aimed at treating addiction and mood disorders, KOR can react to signals that originate independently from multiple biological pathways, so current drug candidates targeting KOR often produce unwanted side effects. Compounds that activate KOR can decrease the rewarding effects of abused drugs, but also induce sedation and depression.

The new findings, from studies of nerve cells in the striatum (an area of the brain involved in motor activity and higher ), reveal a point on the KOR signaling pathway that may prove to be an important indicator of whether drug candidates can produce effects similar to the natural biological effects.

"Standard screening assays can catch differences but those differences may not play out in live tissue," Bohn noted. "Essentially, we have shown an important link between cell-based screening assays and what occurs naturally in animal models."

More information: "Functional Selectivity of 6'-guanidinonaltrindole (6'-GNTI) at Kappa Opioid Receptors in Striatal Neurons," www.jbc.org/content/early/2013/06/17/jbc.M113.476234.full.pdf+html

Related Stories

Brain implant aims to stifle drug highs

Jul 29, 2013

What happens if addicts get no high from the drugs they take? Researchers at Case Western Reserve and Illinois State universities have received a $390,000 National Institute on Drug Abuse grant to help answer the question.

Receptor limits the rewarding effects of food and cocaine

Jul 12, 2011

(Medical Xpress) -- Researchers have long known that dopamine, a brain chemical that plays important roles in the control of normal movement, and in pleasure, reward and motivation, also plays a central role in substance ...

Recommended for you

Leeches help save woman's ear after pit bull mauling

Apr 18, 2014

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

New pain relief targets discovered

Apr 17, 2014

Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. BBSRC-funded researchers at King's College London made the discovery when researching ...

User comments